A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Prezocobix is a prescription medication used for the treatment of human immunodeficiency virus (HIV) infection in adults. It is a combination drug that contains an antiviral and another drug to "boost" the effectiveness of the antiviral.
Prezcobix works by inhibiting HIV protease, which is a necessary protein that helps HIV viral particles to replicate. By shutting down protease, Prezcobix prevents the HIV virus from spreading infection.
Take one tablet by mouth once daily with food.
Prezcobix contains the active ingredients darunavir and cobicistat. Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
Common drug-drug interactions this medication include:
Tell your doctor if you have a history of kidney or liver problems. Your healthcare provider should monitor your kidney and liver function while taking this drug.
If you develop a skin rash or reaction when starting this drug, stop taking it and let your doctor know immediately.
Use caution if you have a history of diabetes.
The most common adverse reactions include:
Prezcobix. Titusville, NJ: Janssen Therapeutics; 2016.